

Yibo Xue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9217477/publications.pdf>

Version: 2024-02-01

9
papers

460
citations

1040056

9
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

810
citing authors

#	ARTICLE	IF	CITATIONS
1	Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. <i>ELife</i> , 2021, 10, .	6.0	23
2	SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca ²⁺ flux to mitochondria. <i>Nature Communications</i> , 2021, 12, 5404.	12.8	20
3	The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer. <i>Nature Cancer</i> , 2021, 2, 1357-1371.	13.2	55
4	CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. <i>Cancer Research</i> , 2020, 80, 444-457.	0.9	88
5	<i>SMARCB1</i> loss induces druggable cyclin <i>D1</i> deficiency via upregulation of <i>MIR17HG</i> in atypical teratoid rhabdoid tumors. <i>Journal of Pathology</i> , 2020, 252, 77-87.	4.5	11
6	eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2158-2170.	4.1	25
7	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. <i>Nature Communications</i> , 2019, 10, 558.	12.8	76
8	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 557.	12.8	125
9	SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. <i>Cell Research</i> , 2015, 25, 445-458.	12.0	36